Menu
Mitoconix Bio
CEO: Gili Hart, PhD

Mitoconix Bio Ltd is pioneering a novel disease modifying strategy for neurodegeneraitve diseases by improving mitochondrial health.

TECHNOLOGY

Disruptions of mitochondria fission (fragmentation) and fusion are implicated in many pathological conditions, including neurodegenerative diseases. Therefore, maintaining a proper balance between fission and fusion is a promising therapeutic approach to prevent cell damage and neurodegeneration. Mitoconix is developing therapeutic peptides designed to selectively inhibit excess mitochondria fission or enhance fusion for maintaining cellular integrity, thereby conferring neuroprotection and functional benefit.

TARGET INDICATION

The target indications are Huntington’s disease (HD), Parkinson’s (PD) and ALS.

LEAD PROGRAM

MTC-1203 is a disease-modifying therapeutic for neurodegenerative diseases. It is a selective peptide inhibitor of pathological mitochondrial fragmentation (fission) and dysfunction; that maintains neuronal health through improved mitochondrial function, ATP production and reduced oxidative stress in culture models of HD, PD and ALS. In vivo efficacy demonstrated in animal models of HD, PD or ALS and beneficial activity in patient-derived cells of HD, familial PD or ALS and sporadic or genetic Alzheimer’s disease (AD).

MTC-1203 A DISEASE-MODIFYING THERAPEUTIC FOR HUNTINGTON’S AND PARKINSON’S DISEASE

Demonstrates in vivo efficacy (improves motor and cognitive function, delays progression) in mouse HD and PD models Reduces level of Htt protein aggregates and neuronal loss (causes of the pathology) in a mouse HD model Reduces neuroinflammation (microglia activation and inflammatory cytokine elevation) Benefits of treatment associated with a decline in peripheral biomarkers Exerts no discernable adverse effects in normal mice even after 5 months of treatment.

MTC-1203 is in preclinical development and is expected to become a disease-modifying therapeutic for treating HD, entering clinical studies late 2018.

www.mitoconix.com

 

 

Back to all Protfolio